RedHill Biopharma (RDHL) said Monday it has received allowance for the composition-of-matter patent application for its proprietary investigational compound RHB-107, a potential oral treatment for COVID-19, from the China National Intellectual Property Administration.
The patent protects the molecular structure of the compound and includes coverage for treatment of SARS-CoV-2, including wild-type and emerging variants, the company said.
RedHill said it acquired the exclusive worldwide rights to RHB-107, excluding China, Hong Kong, Taiwan and Macao, from Germany's Heidelberg Pharma AG, for all indications.
Price: 2.26, Change: -0.15, Percent Change: -6.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.